O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of O6-benzylguanine and implanted carmustine wafers in treating patients who have recurrent malignant glioma.

Key facts

Study ID

NCT00004892

Run by

National Cancer Institute (NCI)

Starts

2000-04-01

Last updated by the study team

2009-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Emory University Hospital - Atlanta — Atlanta, Georgia, United States
• Johns Hopkins Oncology Center — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Comprehensive Cancer Center of Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.